Printer Friendly

PSORIASIS RESEARCH INSTITUTE CLINICAL STUDIES SHOW IGI'S ANTHRASOME PREFERRED

 BUENA, N.J., July 29 /PRNewswire/ -- The Psoriasis Research Institute released to IGI the results of its' second clinical study of IGI's patented Novasomer-based ANTHRASOME(TM) cream, versus Anthraderm(R) and Drithocreme(R), for the treatment of psoriasis. Psoriasis is a chronic skin condition that affects approximately 2 percent of the U.S. population.
 In the first study (extended skin contact), ANTHRASOME was compared with Anthraderm and in the second clinical study (short term skin contact), ANTHRASOME was compared against Drithocreme. Anthraderm and Drithocreme are the most widely used anthralin-based preparations for psoriasis on the U.S. market today.
 The studies, which involved 51 patients, showed that IGI's NOVASOME- encapsulated anthralin was preferred by patients in side-by-side testing against Anthraderm. IGI's formulation was considered at least equivalent to Drithocreme, and superior in one additional important area; skin staining. Patients reported (by a 15 to 1 margin), less skin staining from IGI's formulation. Skin staining is considered a major drawback of other anthralin formulations.
 "IGI's Novasome-based ANTHRASOME was preferred by the majority of patients in our study. ANTHRASOME's performance versus Anthraderm was perceptibly better in the patients' opinions, and equivalent in every category to Drithocreme except in skin stains, where patients clearly preferred ANTHRASOME," said Dr. Martin Katz, a member of the Institute that oversaw the study.
 "We are pleased with the results of these double blind controlled clinical studies with the Psoriasis Research Institute," the company said. "We believe these trials demonstrate the usefulness of our patented NOVASOME technology in certain pharmaceutical applications. IGI's ANTHRASOME cream was preferred by the majority of patients in these clinical tests."
 IGI expects ANTHRASOME will be available on the U.S. market in early 1994.
 IGI is a diversified company engaged in the development, production, and marketing of animal care products, cosmetics, consumer products and human pharmaceuticals.
 -0- 7/29/93
 /CONTACT: Michael Dodge of IGI, 609-697-1441, or Steven Bruce/Rick Stockton of Abernathy/Macgregor/Scanlon, 212-371-5999, for IGI/
 (IG)


CO: IGI Inc. ST: New Jersey IN: MTC SU:

TS -- NY022 -- 7130 07/29/93 09:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 29, 1993
Words:344
Previous Article:BED BATH & BEYOND INC. REPORTS JULY 1993 SALES
Next Article:WISCONSIN WOMAN TAXED WITH A MAALOX MOMENT(TM)
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters